Izdebska J
Kliniki Okulistyki II Wydziału Lekarskiego AM w Warszawie.
Klin Oczna. 1997;99(3):217-20.
Carbonic anhydrase inhibitors (CAI) have been investigated for topical administration in glaucoma therapy during the past few years. Dorzolamide is the first topical CAI to become available for clinical use. CAI's lower intraocular pressure (IOP) by the inhibition of bicarbonate secretion into the posterior chamber by the ciliary epithelium, thereby suppressing aqueous humor production and lowering the IOP. A topical CAI with ocular hypotensive efficacy is comparable with that of oral agents, but without their systemic effects would represent a major advance in medical treatment of glaucoma and ocular hypertension. Data from clinical trials with dorzolamid (Trusopt) have shown this topical carbonic anhydrase inhibitor to be comparable in efficacy to beta-blockers when used as monotherapy, and as effective as pilocarpine when used as an adjunct to beta-blocker therapy. The aim of this paper was to present the results of long-term clinical and experimental studies with dorzolamid (Trusopt).
在过去几年中，人们一直在研究碳酸酐酶抑制剂（CAI）用于青光眼治疗的局部给药。多佐胺是首个可供临床使用的局部CAI。CAI通过抑制睫状体上皮向房水后房分泌碳酸氢盐来降低眼压（IOP），从而抑制房水生成并降低眼压。一种具有降眼压功效的局部CAI，其疗效与口服制剂相当，但无全身作用，这将是青光眼和高眼压症药物治疗的一大进展。多佐胺（Trusopt）临床试验的数据表明，这种局部碳酸酐酶抑制剂作为单一疗法使用时，其疗效与β受体阻滞剂相当，作为β受体阻滞剂治疗的辅助药物使用时，其效果与毛果芸香碱相同。本文的目的是介绍多佐胺（Trusopt）长期临床和实验研究的结果。
